Intelligence Profile
Safety Profile
Known Side Effects
Based on available clinical evidence, thymosin alpha-1 (TA-1) appears to have a relatively favorable safety profile, though comprehensive safety data is limited. The studies primarily focus on efficacy outcomes in hepatitis B and C patients, with limited systematic reporting of adverse events.
Evidence is thin regarding specific side effects. Most studies do not provide detailed adverse event profiles. The available research suggests TA-1 is generally well-tolerated when used in combination with standard antiviral therapies for hepatitis B and C.
Contraindications
No specific contraindications are clearly established in the available evidence. The clinical studies do not systematically report contraindications or provide clear guidance on when TA-1 should be avoided.
Drug Interactions
The available studies demonstrate that TA-1 has been used in combination with:
- Entecavir (for hepatitis B)
- Interferon alpha and ribavirin (for hepatitis C)
These combinations appear to be tolerated based on the study designs, but detailed drug interaction data is not provided in the available evidence.
Populations That Should Exercise Caution
Evidence is insufficient to clearly identify populations that should avoid TA-1. The studies included:
- Patients with hepatitis B-related compensated cirrhosis
- Chronic hepatitis B and C patients
- Cancer patients (non-small cell lung cancer, colorectal cancer)
- Renal dialysis patients
- Sepsis patients
However, safety data specific to vulnerable populations (pregnant women, children, elderly patients, or those with severe organ dysfunction) is not available in the provided evidence.
Clinical Trial Safety
Several phase 2 and phase 3 trials have been completed or are ongoing, including studies in sepsis, cancer, and COVID-19 prevention. A completed phase 3 sepsis trial (NCT02867267) specifically evaluated "efficacy and safety," but detailed safety outcomes are not provided in the available abstracts.
Important Limitations
This safety assessment is significantly limited by the available evidence. Most studies focus on efficacy rather than comprehensive safety evaluation. Systematic adverse event reporting, long-term safety data, and safety in specific populations require further investigation.
Disclaimer: This information is for educational purposes only and should not replace professional medical advice. Consult healthcare providers for personalized medical guidance regarding TA-1 therapy.